

Revision date: 02-Dec-2013 Version: 5.0 Page 1 of 12

# 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

**Product Identifier** 

Material Name: Oxytetracycline Long Acting Injectable Solution 200 mg/mL

Trade Name: Terramycin; Liquamycin; LA-200

Synonyms: TM LA; LA-200

Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Veterinary product used as antibiotic agent

Details of the Supplier of the Safety Data Sheet

Zoetis Inc. 100 Campus Drive, P.O. Box 651

Florham Park, New Jersey 07932 (USA)

Rocky Mountain Poison Control Center Phone: 1-866-531-8896

Product Support/Technical Services Phone: 1-800-366-5288

Zoetis Belgium S.A. Mercuriusstraat 20 1930 Zaventem

Belgium

Emergency telephone number:

CHEMTREC (24 hours): 1-800-424-9300

Contact E-Mail: VMIPSrecords@zoetis.com

**Emergency telephone number:** 

International CHEMTREC (24 hours): +1-703-527-3887

# 2. HAZARDS IDENTIFICATION

Appearance: Clear, yellow to amber sterile solution

Classification of the Substance or Mixture

**GHS - Classification** 

Reproductive Toxicity: Category 1A

**EU Classification:** 

EU Indication of danger: Toxic to reproduction: Category 1

EU Symbol: T

EU Risk Phrases:

R60 - May impair fertility.

R61 - May cause harm to the unborn child.

**Label Elements** 

Signal Word: Danger

Hazard Statements: H360 - May damage fertility or the unborn child

**Precautionary Statements:** P201 - Obtain special instructions before use

P202 - Do not handle until all safety precautions have been read and understood P280 - Wear protective gloves/protective clothing/eye protection/face protection

P308 + P313 - IF exposed or concerned: Get medical attention/advice

P405 - Store locked up

P501 - Dispose of contents/container in accordance with all local and national regulations

Material Name: Oxytetracycline Long Acting Injectable Page 2 of 12

Solution 200 mg/mL

Revision date: 02-Dec-2013 Version: 5.0



Other Hazards

**Short Term:** Exposure to sunlight following contact may result in skin reactions in rare instances. Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on the

developing fetus.

**Known Clinical Effects:** 

Ingestion of this material may cause effects similar to those generally seen in clinical use of antibiotics including gastrointestinal irritation, vomiting, transient diarrhea, nausea, and

abdominal pain. Symptoms of chronic exposure to tetracyclines include redness and swelling of the skin, rash, chills, tooth discoloration, yellowing of the skin and eyes, nausea, vomiting, diarrhea, stomach pain, and chest pain. Clinical use of this drug has caused liver effects

kidney dysfunction.

**Australian Hazard Classification** (NOHSC):

Hazardous Substance. Non-Dangerous Goods.

Note: This document has been prepared in accordance with standards for workplace safety, which

require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases.

Your needs may vary depending upon the potential for exposure in your workplace.

# 3. COMPOSITION/INFORMATION ON INGREDIENTS

#### **Hazardous**

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Monoethanolamine 99% - NF	141-43-5	205-483-3	Xn; R20/21/22 C; R34	Acute Tox. 4 (H302) Skin Corr. 1B (H314) Acute Tox. 4 (H332)	**
Sodium formaldehyde sulfoxylate dihydrate	6035-47-8	Not Listed	Not Listed	Not Listed	< 1
Oxytetracycline hydrochloride	2058-46-0	218-161-2	Repr. Cat.1;R61	Repr. 1A (H360)	20
HYDROCHLORIC ACID	7647-01-0	231-595-7	T; R23 C; R35	Skin Corr.1B (H314) STOT SE 3 (H335)	**
Magnesium oxide	1309-48-4	215-171-9	Not Listed	Not Listed	*
Oxytetracycline Dihydrate	6153-64-6	Not Listed	Repr. Cat.1;R61	Repr. 1A (H360)	20

Ingredient	CAS Number	EU EINECS/ELINCS	EU Classification	GHS Classification	%
		List			
2-Pyrrolidone	616-45-5	210-483-1	Not Listed	Not Listed	*

Material Name: Oxytetracycline Long Acting Injectable Page 3 of 12

Solution 200 mg/mL

Revision date: 02-Dec-2013 Version: 5.0

Additional Information: \* Proprietary

\*\* to adjust pH

Ingredient(s) indicated as hazardous have been assessed under standards for workplace

safety

For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16

## 4. FIRST AID MEASURES

**Description of First Aid Measures** 

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention

immediately.

**Skin Contact:** Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek

medical attention.

**Ingestion:** Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not

induce vomiting unless directed by medical personnel. Seek medical attention immediately.

**Inhalation:** Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of For information on potential signs and symptoms of exposure, See Section 2 - Hazards

**Exposure:** Identification and/or Section 11 - Toxicological Information.

Medical Conditions None known

Aggravated by Exposure:

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

# 5. FIRE-FIGHTING MEASURES

**Extinguishing Media:** Use carbon dioxide, dry chemical, or water spray.

Special Hazards Arising from the Substance or Mixture

**Hazardous Combustion** Formation of toxic gases is possible during heating or fire.

Products:

Fine particles (such as dust and mists) may fuel fires/explosions.

**Advice for Fire-Fighters** 

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

# 6. ACCIDENTAL RELEASE MEASURES

#### Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

#### **Environmental Precautions**

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

#### Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill

**Collecting:** area thoroughly.

\_\_\_\_\_

Material Name: Oxytetracycline Long Acting Injectable Page 4 of 12

Solution 200 mg/mL

Revision date: 02-Dec-2013 Version: 5.0

Additional Consideration for Large Spills:

Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

# 7. HANDLING AND STORAGE

#### **Precautions for Safe Handling**

Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. Keep away from heat, sparks, and flame. Avoid accidental injection. Releases to the environment should be avoided. Use appropriate personal protective equipment.

Conditions for Safe Storage, Including any Incompatibilities

**Storage Conditions:** Store as directed by product packaging.

Specific end use(s): No data available

**ACGIH Threshold Limit Value (TWA)** 

# 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

3 ppm

#### **Control Parameters**

Refer to available public information for specific member state Occupational Exposure Limits.

#### Monoethanolamine 99% - NF

Accin timeonola Emili Value (1777)	o pp
ACGIH Threshold Limit Value (STEL)	6 ppm
Australia STEL	6 ppm
	15 mg/m <sup>3</sup>
Australia TWA	3 ppm
Additional Trans	7.5 mg/m <sup>3</sup>
Austria OEL - MAKs	1 ppm
Austria OLL - WANS	2.5 mg/m <sup>3</sup>
Deleium OFI TMA	•
Belgium OEL - TWA	1 ppm
	2.5 mg/m <sup>3</sup>
Bulgaria OEL - TWA	2.5 mg/m <sup>3</sup>
	1 ppm
Cyprus OEL - TWA	1 ppm
	2.5 mg/m <sup>3</sup>
Czech Republic OEL - TWA	2.5 mg/m <sup>3</sup>
Denmark OEL - TWA	1 ppm
	2.5 mg/m <sup>3</sup>
Estonia OEL - TWA	1 ppm
Estolia OEE - IWA	2.5 mg/m <sup>3</sup>
Finland OEL - TWA	
Finiand OEL - TWA	1 ppm
	2.5 mg/m <sup>3</sup>
France OEL - TWA	1 ppm
	2.5 mg/m <sup>3</sup>
Germany - TRGS 900 - TWAs	2 ppm
	5.1 mg/m <sup>3</sup>
Germany (DFG) - MAK	2 ppm
	5.1 mg/m <sup>3</sup>
Greece OEL - TWA	1 ppm
	2.5 mg/m <sup>3</sup>
Hungary OEL - TWA	2.5 mg/m <sup>3</sup>
Ireland OEL - TWAs	1 ppm
	2.5 mg/m <sup>3</sup>
Italy OEL - TWA	1 ppm
Italy OEL - I WA	i ppiii

00057/4085

2.5 mg/m<sup>3</sup>

Material Name: Oxytetracycline Long Acting Injectable Page 5 of 12

Solution 200 mg/mL

Revision date: 02-Dec-2013 Version: 5.0

# 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

0. EX. 000KE 00KK020	,
Latvia OEL - TWA	0.2 ppm 0.5 mg/m <sup>3</sup>
Lithuania OEL - TWA	3 ppm 8 mg/m <sup>3</sup>
Luxembourg OEL - TWA	1 ppm
Malta OEL - TWA	2.5 mg/m <sup>3</sup> 1 ppm
Netherlands OEL - TWA	2.5 mg/m <sup>3</sup> 2.5 mg/m <sup>3</sup>
Vietnam O EL - TWAs	8 mg/m <sup>3</sup>
OSHA - Final PELS - TWAs:	3 ppm 6 mg/m <sup>3</sup>
Poland OEL - TWA	2.5 mg/m <sup>3</sup>
Portugal OEL - TWA Romania OEL - TWA	3 ppm 1 ppm
Slovakia OEL - TWA	2.5 mg/m <sup>3</sup> 1 ppm
Slovenia OEL - TWA	2.5 mg/m <sup>3</sup> 1 ppm
Spain OEL TWA	2.5 mg/m <sup>3</sup>
Spain OEL - TWA	1 ppm 2.5 mg/m <sup>3</sup>
Sweden OEL - TWAs	3 ppm 8 mg/m <sup>3</sup>
Switzerland OEL -TWAs	2 ppm 5 mg/m <sup>3</sup>
	o mg/m

Oxytetracycline hydrochloride

Zoetis OEL TWA 8-hr 500µg/m<sup>3</sup>

HYDROCHLORIC ACID

ACGIH Ceiling Threshold Limit: Australia PEAK	2 ppm 5 ppm 7.5 mg/m <sup>3</sup>
Austria OEL - MAKs	5 ppm 8 mg/m <sup>3</sup>
Belgium OEL - TWA	5 ppm 8 mg/m <sup>3</sup>
Bulgaria OEL - TWA	8.0 mg/m <sup>3</sup> 5 ppm
Cyprus OEL - TWA	5 ppm 8 mg/m <sup>3</sup>
Czech Republic OEL - TWA Estonia OEL - TWA	8 mg/m <sup>3</sup> 5 ppm 8 mg/m <sup>3</sup>
Germany - TRGS 900 - TWAs	2 ppm 3 mg/m <sup>3</sup>
Germany (DFG) - MAK	2 ppm
Greece OEL - TWA	3.0 mg/m <sup>3</sup> 5 ppm
Hungary OEL - TWA	7 mg/m³ 8 mg/m³

Material Name: Oxytetracycline Long Acting Injectable Page 6 of 12

Solution 200 mg/mL

Ireland OEL - TWAs

Revision date: 02-Dec-2013 Version: 5.0

# 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

5 ppm

		8 mg/m <sup>3</sup>
	Italy OEL - TWA	5 ppm
	•	8 mg/m <sup>3</sup>
	Japan - OELs - Ceilings	5 ppm
		7.5 mg/m <sup>3</sup>
	Latvia OEL - TWA	5 ppm
		8 mg/m <sup>3</sup>
	Lithuania OEL - TWA	5 ppm
		8 mg/m³
	Luxembourg OEL - TWA	5 ppm
	Make OF TWA	8 mg/m <sup>3</sup>
	Malta OEL - TWA	5 ppm 8 mg/m <sup>3</sup>
	Netherlands OEL - TWA	8 mg/m <sup>3</sup>
	Vietnam O EL - TWAs	5 mg/m <sup>3</sup>
	Poland OEL - TWAS	5 mg/m <sup>3</sup>
	Romania OEL - TWA	5 mg/m 5 ppm
	Kollialila OEL - IWA	8 mg/m <sup>3</sup>
	Slovakia OEL - TWA	5 ppm
	olovania ole 1777	8.0 mg/m <sup>3</sup>
	Slovenia OEL - TWA	5 ppm
		8 mg/m <sup>3</sup>
	Spain OEL - TWA	5 ppm
		7.6 mg/m <sup>3</sup>
	Switzerland OEL -TWAs	2 ppm
		3.0 mg/m <sup>3</sup>
wagn	esium oxide	10 mm m/mm3
	ACGIH Threshold Limit Value (TWA) Australia TWA	10 mg/m <sup>3</sup> 10 mg/m <sup>3</sup>
	Austria OEL - MAKs	5 mg/m <sup>3</sup>
	AUSITIA CEL - MANS	10 mg/m <sup>3</sup>
	Belgium OEL - TWA	10 mg/m <sup>3</sup>
	Bulgaria OEL - TWA	10.0 mg/m <sup>3</sup>
	Czech Republic OEL - TWA	5 mg/m <sup>3</sup>
	Denmark OEL - TWA	6 mg/m <sup>3</sup>
	France OEL - TWA	10 mg/m <sup>3</sup>
	Germany (DFG) - MAK	1.5 mg/m <sup>3</sup>
	, , , , , , , , , , , , , , , , , ,	4 mg/m <sup>3</sup>
	Greece OEL - TWA	10 mg/m <sup>3</sup>
		F 73

5 mg/m<sup>3</sup> 6 mg/m<sup>3</sup> **Hungary OEL - TWA** 4 mg/m<sup>3</sup> **Ireland OEL - TWAs** 5 mg/m<sup>3</sup> 10 mg/m<sup>3</sup> Lithuania OEL - TWA 4 mg/m<sup>3</sup> **Vietnam O EL - TWAs** 5 mg/m<sup>3</sup> 15 mg/m<sup>3</sup> **OSHA - Final PELS - TWAs: Poland OEL - TWA** 5 mg/m<sup>3</sup> 10 mg/m<sup>3</sup>

Portugal OEL - TWA 10 mg/m<sup>3</sup>

Material Name: Oxytetracycline Long Acting Injectable Page 7 of 12

Solution 200 mg/mL

Revision date: 02-Dec-2013 Version: 5.0

# 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

 Romania OEL - TWA
 5 mg/m³

 Slovakia OEL - TWA
 1.5 mg/m³

 4 mg/m³
 4 mg/m³

 Spain OEL - TWA
 10 mg/m³

 Switzerland OEL -TWAs
 3 mg/m³

**Oxytetracycline Dihydrate** 

**Zoetis OEL TWA 8-hr** 500μg/m<sup>3</sup>

**Exposure Controls** 

**Engineering Controls:** Engineering controls should be used as the primary means to control exposures. General

room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne

contamination levels below the exposure limits listed above in this section.

Personal Protective Refer to applicable national standards and regulations in the selection and use of personal

**Equipment:** protective equipment (PPE).

Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk

processing operations.

**Eyes:** Wear safety glasses or goggles if eye contact is possible.

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and

for bulk processing operations.

Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate

respirator with a protection factor sufficient to control exposures to below the OEL.

# 9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:Sterile solutionColor:Yellow to amberOdor:No data available.Odor Threshold:No data available.

Molecular Formula: Mixture Molecular Weight: Mixture

Solvent Solubility: No data available Water Solubility: No data available

**pH:** 8.6 - 8.8

Melting/Freezing Point (°C):

Boiling Point (°C):

No data available.

Partition Coefficient: (Method, pH, Endpoint, Value)

No data available

**Decomposition Temperature (°C):** No data available.

Evaporation Rate (Gram/s):

Vapor Pressure (kPa):

Vapor Density (g/ml):

Relative Density:

Specific Gravity:

Viscosity:

No data available
No data available
1.105 - 1.165
No data available

Flammablity:

Autoignition Temperature (Solid) (°C):

Flammability (Solids):

Flash Point (Liquid) (°C):

Upper Explosive Limits (Liquid) (% by Vol.):

Lower Explosive Limits (Liquid) (% by Vol.):

No data available
No data available
No data available

Polymerization: No data available Will not occur

Material Name: Oxytetracycline Long Acting Injectable Page 8 of 12

Solution 200 mg/mL

Revision date: 02-Dec-2013 Version: 5.0

# 10. STABILITY AND REACTIVITY

Reactivity: No data available

Chemical Stability: Stable under normal conditions of use.

**Possibility of Hazardous Reactions** 

Oxidizing Properties: No data available

**Conditions to Avoid:** Fine particles (such as dust and mists) may fuel fires/explosions. **Incompatible Materials:** As a precautionary measure, keep away from strong oxidizers

Hazardous Decomposition No data available

**Products:** 

# 11. TOXICOLOGICAL INFORMATION

# Information on Toxicological Effects

**General Information:** 

The following information describes the toxicity of a chemically-related material. The toxicities of the two materials can be expected to be similar. The remaining information describes the potential hazards of the individual ingredients.

#### Acute Toxicity: (Species, Route, End Point, Dose)

#### Oxytetracycline hydrochloride

Mouse Oral LD50 6696 mg/kg

Mouse SC LD50 > 600mg/kg

Rat SC LD50 800mg/kg

Mouse IV LD50 100mg/kg

Rat IV LD50 302mg/kg

#### 2-Pyrrolidone

Rat Oral LD50 6500 mg/kg

#### Monoethanolamine 99% - NF

Rat Oral LD 50 1720 mg/kg Mouse Oral LD 50 700mg/kg

#### HYDROCHLORIC ACID

Rat Oral LD 50 238-277 mg/kg

#### Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

## Oxytetracycline hydrochloride

13 Week(s) Mouse Oral 3821 mg/kg/day NOAEL None identified

13 Week(s) Rat Oral 3352 mg/kg/day NOAEL Liver

12 Month(s) Dog Oral 125 mg/kg/day NOAEL Male reproductive system

24 Month(s) Dog Oral 250 mg/kg/day NOAEL None identified

14 Day(s) Oral 108 g/kg LOEL Brain

#### Monoethanolamine 99% - NF

90 Day(s) Rat Oral115 g/kg LOEL Liver, Kidney, Ureter, Bladder

30 Week(s) Rat Oral 105 mg/kg LOEL Liver

Material Name: Oxytetracycline Long Acting Injectable Page 9 of 12

Solution 200 mg/mL

Revision date: 02-Dec-2013 Version: 5.0

# 11. TOXICOLOGICAL INFORMATION

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

#### Oxytetracycline hydrochloride

2 Generation Reproductive Toxicity Rat Oral 18 mg/kg/day NOAEL No effects at maximum dose Embryo / Fetal Development Rat Oral 1500 mg/kg/day NOAEL Maternal Toxicity

Embryo / Fetal Development Mouse Oral 2100 mg/kg/day NOAEL Embryotoxicity

#### Monoethanolamine 99% - NF

Reproductive & Fertility-Females Rat Oral =500 mg/kg/day LOAEL Early embryonic development, Reproductive toxicity, Developmental toxicity

#### Oxytetracycline hydrochloride

Bacterial Mutagenicity (Ames) Salmonella Negative

In Vitro Chromosome Aberration Chinese Hamster Ovary (CHO) cells Negative

Sister Chromatid Exchange Chinese Hamster Ovary (CHO) cells Negative

Micronucleus Mouse Negative

Mammalian Cell Mutagenicity Mouse Lymphoma Positive with activation

## Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

#### Oxytetracycline hydrochloride

24 Month(s) Rat Oral, in feed 150 mg/kg/day NOEL Not carcinogenic 103 Week(s) Mouse Oral, in feed 1372 mg/kg/day NOEL Not carcinogenic

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

See below

HYDROCHLORIC ACID

IARC: Group 3 (Not Classifiable)

Material Name: Oxytetracycline Long Acting Injectable Page 10 of 12

Solution 200 mg/mL

Revision date: 02-Dec-2013 Version: 5.0

# 12. ECOLOGICAL INFORMATION

Environmental Overview: The environmental characteristics of this material have not been fully evaluated. Releases to

the environment should be avoided.

**Toxicity:** 

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Oxytetracycline hydrochloride

Oncorhynchus mykiss (Rainbow Trout) ASTM EPA LC50 96 Hours > 116 mg/L

Daphnia magna (Water Flea) ASTM EPA EC50 48 Hours > 102 mg/L

Lepomis macrochirus (Bluegill Sunfish) ASTM EPA LC50 96 Hours > 94.9 mg/L

Selenastrum capricornutum (Green Alga) ISO EC50 72 Hours 4.18 mg/L

Aquatic Toxicity Comments: A greater than symbol (>) indicates that aquatic toxicity was not observed at the maximum

dose tested.

Persistence and Degradability: No data available

Bio-accumulative Potential: No data available

Mobility in Soil: No data available

# 13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State

specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental

releases. This may include destructive techniques for waste and wastewater.

# 14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

# 15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Material Name: Oxytetracycline Long Acting Injectable Page 11 of 12

Solution 200 mg/mL

Revision date: 02-Dec-2013 Version: 5.0

# 15. REGULATORY INFORMATION

Canada - WHMIS: Classifications

WHMIS hazard class:

Class D, Division 2, Subdivision A



Monoethanolamine 99% - NF

CERCLA/SARA 313 Emission reporting

California Proposition 65

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Standard for the Uniform Scheduling
for Drugs and Poisons:

Schedule 5

Schedule 6

EU EINECS/ELINCS List

Not Listed

Not Listed

Not Listed

Not Listed

Not Listed

Schedule 4

Present

Schedule 4

Schedule 5

Schedule 6

Sodium formaldehyde sulfoxylate dihydrate

CERCLA/SARA 313 Emission reporting

California Proposition 65

EU EINECS/ELINCS List

Not Listed

Not Listed

Oxytetracycline hydrochloride

CERCLA/SARA 313 Emission reporting Not Listed

California Proposition 65 developmental toxicity initial date 10/1/91 internal use

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS/ELINCS List

Present
218-161-2

HYDROCHLORIC ACID

CERCLA/SARA 313 Emission reporting 1.0 %
CERCLA/SARA Hazardous Substances 5000 lb
and their Reportable Quantities: 2270 kg
CERCLA/SARA - Section 302 Extremely Hazardous 500 lb

TPQs

CERCLA/SARA - Section 302 Extremely Hazardous 5000 lb

Substances EPCRA RQs
California Proposition 65
Inventory - United States TSCA - Sect. 8(b)
Australia (AICS):
Present
Standard for the Uniform Scheduling
Schedule 5

Standard for the Uniform SchedulingSchedule 5for Drugs and Poisons:Schedule 6EU EINECS/ELINCS List231-595-7

2-Pyrrolidone

CERCLA/SARA 313 Emission reporting

California Proposition 65

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Present

EU EINECS/ELINCS List

Not Listed

10-483-1

Material Name: Oxytetracycline Long Acting Injectable Page 12 of 12

Solution 200 mg/mL

Revision date: 02-Dec-2013 Version: 5.0

# 15. REGULATORY INFORMATION

Magnesium oxide

CERCLA/SARA 313 Emission reporting

California Proposition 65

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Present

EU EINECS/ELINCS List

Not Listed

Not Listed

Present

215-171-9

**Oxytetracycline Dihydrate** 

CERCLA/SARA 313 Emission reporting

California Proposition 65

Australia (AICS):

Present

EU EINECS/ELINCS List

Not Listed

Not Listed

# **16. OTHER INFORMATION**

#### Text of R phrases and GHS Classification abbreviations mentioned in Section 3

H302 - Harmful if swallowed

H314 - Causes severe skin burns and eye damage

H332 - Harmful if inhaled

H360 - May damage fertility or the unborn child

H335 - May cause respiratory irritation

R61 - May cause harm to the unborn child.

R23 - Toxic by inhalation.

R34 - Causes burns.

R35 - Causes severe burns.

R20/21/22 - Harmful by inhalation, in contact with skin and if swallowed.

**Data Sources:** The data contained in this MSDS may have been gathered from confidential internal sources,

raw material suppliers, or from the published literature.

**Reasons for Revision:** Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking.

Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 4 - First Aid Measures. Updated Section 7 - Handling and Storage. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 12 -

Ecological Information. Updated Section 15 - Regulatory Information.

Prepared by: Toxicology and Hazard Communication

Zoetis Global Risk Management

Zoetis Inc. believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

#### **End of Safety Data Sheet**